| abstract |
FIELD: medicine. SUBSTANCE: invention relates to agents for magnetic-resonance opaque diagnosis and can be used in experimental and clinical investigations. Composition is aqueous solution containing 0.5 mmole/l complex of gadolinium disodium or dipiperazine salt with diethylenetriaminopentaacetic aced (gadopentate), pH is 5.0-8.5, and 0.5-5 wt.-% of medicinal drug polymer B. Solution has polyvinylpyrrolidone solution (molecular mass is 12 000 ± 1 500 Da) or dextran (molecular mass is 60 000 ± 500 Da, not above) or polyethylene glycol (molecular mass is 1 500 ± 500 Da) as medicinal polymer. Composition is prepared by interaction of gadolinium oxide or carbonate with diethylenetriaminopentaacetic acid in aqueous medium and dry medicinal polymer is added to obtained aqueous solution of gadopentate disodium or dipiperazine salt up to concentration 0.5-5%. Relative content of gadolinium in complex is 26.5% (as measured for gadopentate disodium salt). Viscosity of obtained composition at 20 C is 3.5 cP, not above, that significantly lower as compared with the known preparation "Megnevist". Value UD 50 (in rats) of obtained composition is below 8.5 mmole/kg that better as compared with this index of "Magnevist". Mean effectiveness of spin-latticed relaxation of 1 H in buffer solution (20 MHz, 30 C, mmole x c -1 ) is 7.5, not less, that ensures to use its for medical-biological studies. EFFECT: improved degree of contrast of image in body survey, decreased adverse effect of opaque agent. 4 cl, 1 tbl, 9 ex |